- In June 2025, the Michael J. Fox Foundation announced that ND0612, a 24‑hour under‑the‑skin infusion of levodopa/carbidopa, was formally resubmitted to the FDA after addressing prior safety and manufacturing concerns. Approval could bring a third continuous infusion treatment to patients experiencing motor fluctuations
- In February 2025, the FDA approved Onapgo (apomorphine hydrochloride), the second under‑the‑skin infusion therapy for Parkinson’s disease in the U.S. It provides continuous symptom control and is the first apomorphine infusion approved
- In April 2025, tavapadon, a once-daily oral dopamine D₁/D₅ partial agonist developed by AbbVie, demonstrated rapid and sustained motor improvement in early-stage Parkinson’s during TEMPO trials. It is now being evaluated for FDA approval
- In April 2025, BlueRock Therapeutics published 18‑month Phase 1 data for its cell therapy bemdaneprocel in Nature. Safe and without serious adverse events, it is now poised to enter Phase 3 trials in
